AbbVie Inc. Daily Market Performance – April 24, 2026
On April 24, 2026, AbbVie Inc. (NYSE: ABBV) experienced a notable decline in its stock price, closing at $198.71, down from the previous day's close of $200.95. This represents a decrease of $2.24 or approximately 1.11%. The stock opened at $198.93, reached a high of $200.25, and dropped to a low of $197.14 during the trading session. The total trading volume for the day was approximately 7.6052 million shares, indicating significant trading activity.
Intraday Price Movements
AbbVie's stock showed volatility throughout the day, with prices fluctuating between the high of $200.25 and the low of $197.14. The highest price was reached shortly after the market opened, reflecting initial investor optimism. However, selling pressure increased during the session, pushing the price down before settling at the closing level of $198.71. These fluctuations align with broader market reactions to recent news and the anticipation of upcoming earnings.
Key News and Market Influences
- FDA Complete Response Letter (CRL): AbbVie received a Complete Response Letter from the U.S. Food and Drug Administration concerning its application for TrenibotE, an anti-wrinkle treatment. The FDA cited manufacturing issues as the reason for the CRL. This regulatory setback has raised concerns about the product's market potential and revenue contribution, which was a primary driver behind the stock's decline. The news was widely reported by financial media, including Yahoo Finance and GuruFocus.
- Earnings Expectations: AbbVie is scheduled to report its first-quarter 2026 earnings on April 29, 2026. Analysts expect a year-over-year increase in earnings per share (EPS) to approximately $2.93, signaling a 19.1% growth compared to the prior year. However, the recent regulatory challenges have introduced caution among investors regarding these forecasts.
- Market Context: Despite AbbVie's stock decline, the broader market showed strength, with the S&P 500 index hitting new all-time highs. This divergence indicates that AbbVie's underperformance was company-specific rather than indicative of overall market trends. The healthcare sector faced increased scrutiny, with AbbVie lagging behind peers.
- Analyst Ratings and Future Outlook: Analyst opinions on AbbVie remain mixed. Some maintain a positive stance based on the company’s fundamentals and growth prospects, while others have revised price targets downward following the regulatory news. AbbVie has also lowered its full-year adjusted EPS guidance to a range of $13.96 to $14.16, adding complexity to the stock’s outlook.
- Investment Activity: The trading volume of approximately 7.6 million shares reflects active participation from institutional and retail investors. The volume and price movement suggest investors are balancing concerns about regulatory risks against optimism for upcoming earnings results.
Conclusion
On April 24, 2026, AbbVie Inc. encountered a challenging trading day marked by a stock price decline influenced primarily by regulatory news regarding the FDA’s Complete Response Letter for TrenibotE. The stock’s intraday volatility and trading volume highlight investor reactions to this setback combined with anticipation of the upcoming first-quarter earnings report. While the broader U.S. stock market continued to perform strongly, AbbVie’s specific challenges underscore the impact of company-specific news on stock performance. Moving forward, investors will focus on earnings outcomes and any further developments related to regulatory approvals and the company’s product pipeline.
Explore more exclusive insights at nextfin.ai.
